glp 1 heart failure GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential Epicardial Fat Paradox and Differential

Trikafta/Kaftrio (elexacaftor/tezacaftor/ivacaftor) Disease area(s): Respiratory/rare disease Manufacturer(s): Vertex Pharmaceuticals Incorporated 2024 Sales (USD): $10.24 billion Why it sold so well: Trikafta (marketed as Kaftrio outside the US), a combination therapy of elexacaftor, tezacaftor and ivacaftor, was the primary driver of Vertex Pharmaceuticals strong commercial performance in 2024

This includes legislation like the Treat and Reduce Obesity Act, aimed at increasing accessibility for lower-income patients

While off-licence prescribing can be common in some areas of medicine [60], it can also pose safety risks [61]particularly when medications are accessed without appropriate clinical supervision

She said she wished she had been warned of those risks before

Sakai Y, Suzuki A, Mugishima K, et al

It reflects a shift in the body overall inflammatory state that affects appearance from head to toe